Sheng-Shun Yang

发表

Mutations in the NS5A and E2‐PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin

Ding‐Shinn Chen, J. Kao, M. Lai, 2003, Liver international : official journal of the International Association for the Study of the Liver.

Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy.

Shu-Chuan Chang, Shun‐Sheng Wu, C. Peng, 2008, Journal of the Formosan Medical Association = Taiwan yi zhi.

Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer.

Chien-Jen Chen, Mei-Hwei Chang, Ding‐Shinn Chen, 2016, Gastroenterology.

Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage.

L. Jeng, M. Ho, Pei-Jer Chen, 2009, Journal of hepatology.

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence.

L. Jeng, M. Ho, Pei-Jer Chen, 2014, World journal of gastroenterology.

Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan

Mei-Hsuan Lee, J. Kao, Chun-Jen Liu, 2021, Infectious Diseases and Therapy.

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

Chien-Jen Chen, Mei-Hwei Chang, Ding‐Shinn Chen, 2009, Journal of the National Cancer Institute.

Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial

Ding‐Shinn Chen, Pei-Jer Chen, J. Kao, 2015, Scientific Reports.

Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial

Ding‐Shinn Chen, Pei-Jer Chen, J. Kao, 2015, Scientific Reports.

Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial

Ding‐Shinn Chen, Pei-Jer Chen, J. Kao, 2014, Gut.

Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy

T. Hsieh, W. Hung, Hsin-Hua Chen, 2019, Annals of the rheumatic diseases.

Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment

Pei-Jer Chen, T. Tseng, J. Kao, 2021, Alimentary pharmacology & therapeutics.

Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals

J. Kao, Chia-Chi Wang, Han‐Chieh Lin, 2022, Viruses.

Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

J. Kao, Chun-Jen Liu, C. Hung, 2021, Hepatology International.

Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment

Ding‐Shinn Chen, T. Tseng, J. Kao, 2020, Journal of viral hepatitis.

The Ultra-Short Virological Dynamics in Response to Entecavir or Lamivudine during Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation

Sheng-Shun Yang, Chi-yi Chen, Teng‐Yu Lee, 2018, Antiviral therapy.

Interleukin 28B Genetic Polymorphisms Play a Minor Role in Identifying Optimal Treatment Duration in HCV Genotype 1 Slow Responders to Pegylated Interferon plus Ribavirin

Ding‐Shinn Chen, T. Tseng, J. Kao, 2012, Antiviral therapy.

High Risk of clinical relapse in HBV-infected patients after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy.

Ding‐Shinn Chen, T. Tseng, J. Kao, 2020, The Journal of infectious diseases.

Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C

J. Kao, Chi-Sen Chang, Gran‐Hum Chen, 2006, Journal of gastroenterology and hepatology.

Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non‐cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis

Ding‐Shinn Chen, J. Kao, Chun-Jen Liu, 2019, Journal of gastroenterology and hepatology.

Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy

Ding‐Shinn Chen, T. Tseng, J. Kao, 2012, Antiviral therapy.

Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study.

Shu-Chuan Chang, H. Lee, Yueh-Chin Chung, 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan

J. Kao, T. Su, Chia-Chi Wang, 2016, Hepatology International.

Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.

H. Kuo, Ming‐Lung Yu, R. Chien, 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.

Pegylated Interferon-α2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis

Ding‐Shinn Chen, J. Kao, Chun-Jen Liu, 2013, Annals of Internal Medicine.

Hepatitis B virus-related mortality in rheumatoid arthritis patients undergoing long-term low-dose glucocorticoid treatment: A population-based study.

Shu-Chuan Chang, Hsin-Hua Chen, H. Lee, 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

Detection of the Hepatitis B Virus X Protein (HBx) Antigen and Anti-HBx Antibodies in Cases of Human Hepatocellular Carcinoma

Yan-Hsiung Wang, Cheng‐Chung Wu, G. Hwang, 2003, Journal of Clinical Microbiology.

Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients

Chien-Jen Chen, Ding‐Shinn Chen, Sheng-Nan Lu, 2006, Liver international : official journal of the International Association for the Study of the Liver.

Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon-α-2A Therapy

Ding‐Shinn Chen, T. Tseng, J. Kao, 2011, Antiviral therapy.

Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

T. Tseng, J. Kao, T. Su, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Direct-Acting Antiviral Drugs Reduce Fibromyalgia Symptoms in Patients with Chronic Hepatitis C

Der-Yuan Chen, Yi-Hsing Chen, Tsai-Ling Liao, 2022, Journal of clinical medicine.

Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy

T. Hsieh, Yi-Ming Chen, Der-Yuan Chen, 2011, Annals of the rheumatic diseases.

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

Ding‐Shinn Chen, T. Tseng, J. Kao, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection

J. Kao, Sheng-Shun Yang, 2016, Hepatology International.

Asunaprevir-containing regimens for the treatment of hepatitis C virus infection

J. Kao, Sheng-Shun Yang, 2015, Expert review of gastroenterology & hepatology.

Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review.

Yi-Ming Chen, Der-Yuan Chen, Sheng-Shun Yang, 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)

K. Simon, T. Hassanein, A. Tran, 2019, Hepatology.

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan

J. Kao, Chun-Jen Liu, S. Yeh, 2021, Viruses.

Long‐term trends and geographic variations in the survival of patients with hepatocellular carcinoma: Analysis of 11 312 patients in Taiwan

Chien-Jen Chen, Ding‐Shinn Chen, Sheng-Nan Lu, 2006, Journal of gastroenterology and hepatology.

Advances in the Era of Direct-Acting Antivirals for Hepatitis C in Patients with Unresectable Hepatocellular Carcinoma

Shou-Wu Lee, Sheng-Shun Yang, H. Tsai, 2021, Digestive Diseases.

Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment

J. Kao, Chun-Jen Liu, Chun-Chao Chang, 2021, Gut.

Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis

Ding‐Shinn Chen, J. Kao, Chun-Jen Liu, 2020, Scientific Reports.

Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis

Ding‐Shinn Chen, J. Kao, Chun-Jen Liu, 2020, Scientific Reports.

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis

J. Kao, Chun-Jen Liu, Chun-Chao Chang, 2021, Clinical and molecular hepatology.

A case of non-O1 and non-O139 Vibrio cholerae septicemia with endophthalmitis in a cirrhotic patient.

Ya-Ling Lee, Yu-Hui Lin, Sheng-Shun Yang, 2008, Japanese journal of infectious diseases.

Secular trends and geographic variations of hepatitis B virus and hepatitis C virus‐associated hepatocellular carcinoma in Taiwan

Chien-Jen Chen, Ding‐Shinn Chen, Sheng-Nan Lu, 2006, International journal of cancer.

Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?

J. Kao, Sheng-Shun Yang, Shih-Jer Hsu, 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease

Y. Chang, Horng-Rong Chang, Y. Chuang, 2021, Journal of viral hepatitis.

Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg‐negative, HBcAb‐positive rheumatoid arthritis patients: A long‐term, real‐world observation

T. Hsieh, Hsin-Hua Chen, Yi-Ming Chen, 2019, International journal of rheumatic diseases.

Hepatitis C Virus-Induced Exosomal MicroRNAs and Toll-Like Receptor 7 Polymorphism Regulate B-Cell Activating Factor

S. Hsieh, Hung-Jen Liu, Yi-Ming Chen, 2021, mBio.

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan

J. Kao, Chun-Jen Liu, Chia-Chi Wang, 2021, Liver international : official journal of the International Association for the Study of the Liver.

[610] AN OPEN-LABEL, COMPARATIVE, MULTICENTER STUDY OF PEGINTERFERON a-2a PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C/HEPATITIS B CO-INFECTION VERSUS CHRONIC HEPATITIS C MONOINFECTION: AN INTERIM REPORT

Ding‐Shinn Chen, Sheng-Nan Lu, J. Kao, 2007 .

Effectiveness of case management for adult patients with chronic liver disease: a systematic review

Shu-Chuan Chang, Sheng-Shun Yang, Yi-Chen Lin, 2012, JBI library of systematic reviews.

Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ

Shu-Chuan Chang, Tsai-Chung Li, Yueh-Chin Chung, 2014, Health and Quality of Life Outcomes.

Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study

Ding‐Shinn Chen, T. Tseng, J. Kao, 2018, Scientific Reports.

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan

J. Kao, Chun-Jen Liu, Chia-Chi Wang, 2021, Scientific Reports.

Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV Registry Program (TACR).

J. Kao, Chun-Jen Liu, Chia-Chi Wang, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Assessment of Educational Needs and Quality of Life of Chronic Hepatitis Patients

Shu-Chuan Chang, Hsiu-Ju Chang, W. Tsai, 2017, BMC Health Services Research.

Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study

T. Tseng, J. Kao, Chun-Jen Liu, 2022, Open forum infectious diseases.

Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.

J. Kao, Chun-Jen Liu, Chia-Chi Wang, 2022, Journal of the Formosan Medical Association = Taiwan yi zhi.

527 SUSTAINED HCV CLEARANCE AND INCREASED HBSAG SEROCLEARANCE IN PATIENTS WITH DUAL CHRONIC HEPATITIS C AND B POST-PEGINTERFERON ALFA-2A AND RIBAVIRIN TREATMENT: A 5-YEAR FOLLOW-UP

Ding‐Shinn Chen, Sheng-Nan Lu, J. Kao, 2012 .

Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy

T. Hsieh, Yi-Ming Chen, Der-Yuan Chen, 2011 .

Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas

Chien-Jen Chen, Ding‐Shinn Chen, Sheng-Nan Lu, 2009, Hepatology international.

Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

J. Kao, Chun-Jen Liu, Y. Shih, 2023, Hepatology International.

IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.

J. Kao, J. Chuang, Y. Hsieh, 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.